Clevidipine for the treatment of severe hypertension in adults

Clinical Therapeutics

Volumn 32, Issue 1, 2010, Pages 11-23

  Nguyen, Huan M ^a   Ma, Karlene ^b   Pham, David Q ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

clevidipine; hypertensive emergency; perioperative hypertension; postoperative hypertension; preoperative hypertension; severe hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLEVIDIPINE; PYRIDINE DERIVATIVE;

BLOOD PRESSURE; DRUG EFFECT; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; REVIEW;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; HYPERTENSION; INFUSIONS, INTRAVENOUS; PYRIDINES;

MLCS; MLOWN;

EID: 77952298937     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.01.025     Document Type: Article

References (42)

1. US Dept of Health and Human Services (HHS), National Institutes of Health (NIH), National Heart, Lung, and Blood Institute. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). http://www.nhlbi.nih.gov/guidelines/hypertension/ Accessed March 12, 2009.
2. Goldman, L, Caldera, DL, Risks of general anesthesia and elective operation in the hypertensive patient. Anesthesiology 50 (1979), 285–292.
3. Haas, CE, LeBlanc, JM, Acute postoperative hypertension: A review of therapeutic options. Am J Health Syst Pharm. 61 (2004), 1661–1675.
4. Cooper, TJ, Clutton-Brock, TH, Jones, SN, et al. Factors relating to the development of hypertension after cardiopulmonary bypass. Br Heart J. 54 (1985), 91–95.
5. Estafanous, FG, Tarazi, RC, Systemic arterial hypertension associated with cardiac surgery. Am J Cardiol. 46 (1980), 685–694.
6. Estrad, BL, Barletta, JF, Treatment of hypertension in the perioperative patient. Ann Pharmacother. 34 (2000), 66–79.
7. Forrest, JB, Rehder, K, Cahalan, MK, Goldsmith, CH, Multicenter study of general anesthesia. III. Predictors of severe perioperative adverse outcomes [published correction appears in Anesthesiology. 1992;77:222]. Anesthesiology 76 (1992), 3–15.
8. Nordlander, M, Sjöquist, PO, Ericsson, H, Rydén, L, Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 22 (2004), 227–250.
9. Vuylsteke, A, Feneck, RO, Jolin-Mellgård, A, et al. Perioperative blood pressure control: A prospective survey of patient management in cardiac surgery. J Cardiothorac Vasc Anesth. 14 (2000), 269–273.
10. Cleviprex (clevidipine butyrate) injectable emulsion for intravenous use [package insert], 2008, The Medicines Company, Parsippany, NJ.
11. Physicians' Desk Reference, 2008, Thomson Reuters, Montvale, NJ.
12. van Zwieten, PA, van Wezel, HB, Antihypertensive drug treatment in the perioperative period. J Cardiothorac Vasc Anesth. 7 (1993), 213–226.
13. Cook, E, Clifton, GG, Vargas, R, et al. Pharmacokinetics, pharmacodynamics, and minimum effective clinical dose of intravenous nicardipine. Clin Pharmcol Ther. 47 (1990), 706–718.
14. Ericsson, H, Tholander, B, Björkman, JA, et al. Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. Drug Metab Dispos. 27 (1999), 558–564.
15. Norlander, M, Sjöquist, PO, Ericsson, H, Rydén, L, Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 22 (2004), 227–250.
16. Kieler-Jensen, N, Jolin-Mellgård, A, Nordlander, M, Ricksten, SE, Coronary and systemic hemodynamic effects of clevidipine, an ultra-short-acting calcium antagonist, for treatment of hypertension after coronary artery surgery. Acta Anaesthesiol Scand. 44 (2000), 186–193.
17. Segawa, D, Sjöquist, PO, Nordlander, M, et al. Cardiac inotropic vs. chronotropic selectivity of isradipine, nifedipine and clevidipine, a new ultrashort-acting dihydropyridine. Eur J Pharmacol. 380 (1999), 123–128.
18. Ericsson, H, Tholander, B, Regårdh, CG, In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashortacting calcium antagonist metabolized by esterases, in different animal species and man. Eur J Pharm Sci. 8 (1999), 29–37.
19. Ericsson, H, Fakt, C, Höglund, L, et al. Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion. Eur J Clin Pharmacol. 55 (1999), 61–67.
20. Gourine, A, Gonon, A, Sjöquist, PO, Pernow, J, Short-acting calcium antagonist clevidipine protects against reperfusion injury via local nitric oxide-related mechanisms in the jeopardized myocardium. Cardiovasc Res. 51 (2001), 100–107.
21. Segawa, D, Sjöquist, PO, Wang, QD, et al. Calcium antagonist protects the myocardium from reperfusion injury by interfering with mechanisms directly related to reperfusion: An experimental study with the ultrashort-acting calcium antagonist clevidipine. J Cardiovasc Pharmacol. 36 (2000), 338–343.
22. Wang, QD, Sagawa, D, Ericsson, H, et al. Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: Part I. J Cardiovasc Pharmacol. 40 (2002), 228–234.
23. Segawa, D, Sjöquist, PO, Wang, QD, et al. Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: Part II. J Cardiovasc Pharmacol. 40 (2002), 339–345.
24. Gourine, AV, Pernow, J, Poputnikov, DM, Sjöquist, PO, Calcium antagonist clevidipine reduces myocardial reperfusion injury by a mechanism related to bradykinin and nitric oxide. J Cardiovasc Pharmacol. 40 (2002), 564–570.
25. Odenstedt, J, Månsson, C, Grip, L, Failure to demonstrate myocardial protective effects of the ultra short-acting calcium antagonist clevidipine in a closed-chest reperfusion porcine model. J Cardiovasc Pharmacol. 44 (2004), 407–415.
26. Stephens, CT, Jandhyala, BS, Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats. Clin Exp Hypertens 24 (2002), 301–313.
27. Ericsson, H, Fakt, C, Jolin-Mellgård, A, et al. Clinical and pharmacokinetic results with a new ultrashortacting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers. Br J Clin Pharmacol. 47 (1999), 531–538.
28. Haas, AR, Marik, PE, Current diagnosis and management of hypertensive emergency. Semin Dial. 19 (2006), 502–512.
29. Aronson, S, Dyke, CM, Stierer, KA, et al. The ECLIPSE trials: Comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg. 107 (2008), 1110–1121.
30. Aronson, S, Kereiakes, D, Levy, J, et al. Blood pressure control is an independent predictor of short-term mortality in cardiac surgery patients: Analysis from the three randomized ECLIPSE trials. Presented at: 56th Annual Scientific Session of the American College of Cardiology, New Orleans, La, March 24–27, 2007.
31. Aronson, S, Stierer, K, Levy, J, et al. Perioperative blood pressure control predicts renal dysfunction in cardiac surgery patients. Presented at: Annual Meeting of the American Society of Anesthesiologists, San Francisco, Calif., October 13–17, 2007.
32. Bailey, JM, Lu, W, Levy, JH, et al. Clevidipine in adult cardiac surgical patients: A dose-finding study. Anesthesiology 96 (2002), 1086–1094.
33. Levy, JH, Mancao, MY, Gitter, R, et al. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: The results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1. Anesth Analg. 105 (2007), 918–925.
34. Pollack, CV, Varon, J, Garrison, NA, et al. Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension. Ann Emerg Med. 53 (2009), 329–338.
35. Powroznyk, AV, Vuylsteke, A, Naughton, C, et al. Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery. Eur J Anaesthesiol. 20 (2003), 697–703.
36. Singla, N, Warltier, DC, Gandhi, SD, et al., ESCAPE-2 Study Group. Treatment of acute postoperative hypertension in cardiac surgery patients: An efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (ESCAPE-2), a randomized, double-blind, placebo-controlled trial. Anesth Analg. 107 (2008), 59–67.
37. Maisel, WH, Rawn, JD, Stevenson, WG, Atrial fibrillation after cardiac surgery. Ann Intern Med. 135 (2001), 1061–1073.
38. Matthew, JP, Fontes, ML, Tudor, IC, et al., Investigators of the Ischemia Research and Education Foundation, Multicenter Study of Perioperative Ischemia Research Group. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 291 (2004), 1720–1729.
39. Zhang, JG, Dehal, SS, Ho, T, et al. Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 34 (2006), 734–737.
40. Lexi-Comp ONLINE. Hudson, Ohio: Lexi-Comp, Inc. http://online.lexi.com Accessed July 13, 2009.
41. Clevidipine (Cleviprex) for IV treatment of severe hypertension. Med Lett Drugs Ther. 50 (2008), 73–74.
42. Red Book: Pharmacy's Fundamental Reference, 2008 ed., 2008, Thomson, Montvale, NJ.